MersV1, PubMed, Curation, bibRecord, 000910

Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.

Identifieur interne : 000910 ( PubMed/Curation ); précédent : 000909; suivant : 000911

Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.

Auteurs : Seo-Yeon Jung [Corée du Sud] ; Kyung Won Kang [Corée du Sud] ; Eun-Young Lee [Corée du Sud] ; Dong-Won Seo [Corée du Sud] ; Hong-Lim Kim [Corée du Sud] ; Hak Kim [Corée du Sud] ; Taewoo Kwon [Corée du Sud] ; Hye-Lim Park [Corée du Sud] ; Hun Kim [Corée du Sud] ; Sang-Myeong Lee [Corée du Sud] ; Jae-Hwan Nam [Corée du Sud]

Source :

Vaccine [ 1873-2518 ] ; 2018.

RBID : pubmed:29739720

Descripteurs français

English descriptors

KwdEn :
- Adenoviruses, Human (genetics), Adenoviruses, Human (immunology), Adjuvants, Immunologic (administration & dosage), Alum Compounds (administration & dosage), Animals, Antibodies, Neutralizing (biosynthesis), Antibodies, Viral (biosynthesis), Coronavirus Infections (immunology), Coronavirus Infections (prevention & control), Coronavirus Infections (virology), Female, Humans, Immunization Schedule, Immunization, Secondary (methods), Immunogenicity, Vaccine, Immunoglobulin G (biosynthesis), Lymphocyte Activation (drug effects), Mice, Mice, Inbred BALB C, Middle East Respiratory Syndrome Coronavirus (drug effects), Middle East Respiratory Syndrome Coronavirus (genetics), Middle East Respiratory Syndrome Coronavirus (immunology), Nanoparticles (administration & dosage), Nanoparticles (chemistry), Spike Glycoprotein, Coronavirus (administration & dosage), Spike Glycoprotein, Coronavirus (genetics), Spike Glycoprotein, Coronavirus (immunology), Th1 Cells (drug effects), Th1 Cells (immunology), Th1 Cells (virology), Th2 Cells (drug effects), Th2 Cells (immunology), Th2 Cells (virology), Viral Vaccines (administration & dosage), Viral Vaccines (genetics), Viral Vaccines (immunology).
MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Alum Compounds, Spike Glycoprotein, Coronavirus, Viral Vaccines.
- chemical , biosynthesis : Antibodies, Neutralizing, Antibodies, Viral, Immunoglobulin G.
- administration & dosage : Nanoparticles.
- chemistry : Nanoparticles.
- drug effects : Lymphocyte Activation, Middle East Respiratory Syndrome Coronavirus, Th1 Cells, Th2 Cells.
- genetics : Adenoviruses, Human, Middle East Respiratory Syndrome Coronavirus, Spike Glycoprotein, Coronavirus, Viral Vaccines.
- immunology : Adenoviruses, Human, Coronavirus Infections, Middle East Respiratory Syndrome Coronavirus, Spike Glycoprotein, Coronavirus, Th1 Cells, Th2 Cells, Viral Vaccines.
- methods : Immunization, Secondary.
- prevention & control : Coronavirus Infections.
- virology : Coronavirus Infections, Th1 Cells, Th2 Cells.
- Animals, Female, Humans, Immunization Schedule, Immunogenicity, Vaccine, Mice, Mice, Inbred BALB C.

Abstract

The Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic and zoonotic virus with a fatality rate in humans of over 35%. Although several vaccine candidates have been developed, there is still no clinically available vaccine for MERS-CoV. In this study, we developed two types of MERS-CoV vaccines: a recombinant adenovirus serotype 5 encoding the MERS-CoV spike gene (Ad5/MERS) and spike protein nanoparticles formulated with aluminum (alum) adjuvant. Next, we tested a heterologous prime-boost vaccine strategy, which compared priming with Ad5/MERS and boosting with spike protein nanoparticles and vice versa, with homologous prime-boost vaccination comprising priming and boosting with either spike protein nanoparticles or Ad5/MERS. Although both types of vaccine could induce specific immunoglobulin G against MERS-CoV, neutralizing antibodies against MERS-CoV were induced only by heterologous prime-boost immunization and homologous immunization with spike protein nanoparticles. Interestingly, Th1 cell activation was induced by immunization schedules including Ad5/MERS, but not by those including only spike protein nanoparticles. Heterologous prime-boost vaccination regimens including Ad5/MERS elicited simultaneous Th1 and Th2 responses, but homologous prime-boost regimens did not. Thus, heterologous prime-boost may induce longer-lasting immune responses against MERS-CoV because of an appropriate balance of Th1/Th2 responses. However, both heterologous prime-boost and homologous spike protein nanoparticles vaccinations could provide protection from MERS-CoV challenge in mice. Our results demonstrate that heterologous immunization by priming with Ad5/MERS and boosting with spike protein nanoparticles could be an efficient prophylactic strategy against MERS-CoV infection.

DOI: 10.1016/j.vaccine.2018.04.082
PubMed: 29739720

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000910

Links to Exploration step

pubmed:29739720

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.</title>
<author><name sortKey="Jung, Seo Yeon" sort="Jung, Seo Yeon" uniqKey="Jung S" first="Seo-Yeon" last="Jung">Seo-Yeon Jung</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kang, Kyung Won" sort="Kang, Kyung Won" uniqKey="Kang K" first="Kyung Won" last="Kang">Kyung Won Kang</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology, Chonbuk National University, Iksan 570-752, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Biotechnology, Chonbuk National University, Iksan 570-752</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lee, Eun Young" sort="Lee, Eun Young" uniqKey="Lee E" first="Eun-Young" last="Lee">Eun-Young Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Seo, Dong Won" sort="Seo, Dong Won" uniqKey="Seo D" first="Dong-Won" last="Seo">Dong-Won Seo</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology, Chonbuk National University, Iksan 570-752, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Biotechnology, Chonbuk National University, Iksan 570-752</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Hong Lim" sort="Kim, Hong Lim" uniqKey="Kim H" first="Hong-Lim" last="Kim">Hong-Lim Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>Seoul St. Mary's Hospital, School of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Seoul St. Mary's Hospital, School of Medicine, The Catholic University of Korea, Seoul 06591</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Hak" sort="Kim, Hak" uniqKey="Kim H" first="Hak" last="Kim">Hak Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kwon, Taewoo" sort="Kwon, Taewoo" uniqKey="Kwon T" first="Taewoo" last="Kwon">Taewoo Kwon</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Park, Hye Lim" sort="Park, Hye Lim" uniqKey="Park H" first="Hye-Lim" last="Park">Hye-Lim Park</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Hun" sort="Kim, Hun" uniqKey="Kim H" first="Hun" last="Kim">Hun Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lee, Sang Myeong" sort="Lee, Sang Myeong" uniqKey="Lee S" first="Sang-Myeong" last="Lee">Sang-Myeong Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology, Chonbuk National University, Iksan 570-752, Republic of Korea. Electronic address: leesangm@jbnu.ac.kr.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Biotechnology, Chonbuk National University, Iksan 570-752</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nam, Jae Hwan" sort="Nam, Jae Hwan" uniqKey="Nam J" first="Jae-Hwan" last="Nam">Jae-Hwan Nam</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea. Electronic address: jhnam@catholic.ac.kr.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:29739720</idno>
<idno type="pmid">29739720</idno>
<idno type="doi">10.1016/j.vaccine.2018.04.082</idno>
<idno type="wicri:Area/PubMed/Corpus">000910</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000910</idno>
<idno type="wicri:Area/PubMed/Curation">000910</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000910</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.</title>
<author><name sortKey="Jung, Seo Yeon" sort="Jung, Seo Yeon" uniqKey="Jung S" first="Seo-Yeon" last="Jung">Seo-Yeon Jung</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kang, Kyung Won" sort="Kang, Kyung Won" uniqKey="Kang K" first="Kyung Won" last="Kang">Kyung Won Kang</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology, Chonbuk National University, Iksan 570-752, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Biotechnology, Chonbuk National University, Iksan 570-752</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lee, Eun Young" sort="Lee, Eun Young" uniqKey="Lee E" first="Eun-Young" last="Lee">Eun-Young Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Seo, Dong Won" sort="Seo, Dong Won" uniqKey="Seo D" first="Dong-Won" last="Seo">Dong-Won Seo</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology, Chonbuk National University, Iksan 570-752, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Biotechnology, Chonbuk National University, Iksan 570-752</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Hong Lim" sort="Kim, Hong Lim" uniqKey="Kim H" first="Hong-Lim" last="Kim">Hong-Lim Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>Seoul St. Mary's Hospital, School of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Seoul St. Mary's Hospital, School of Medicine, The Catholic University of Korea, Seoul 06591</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Hak" sort="Kim, Hak" uniqKey="Kim H" first="Hak" last="Kim">Hak Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kwon, Taewoo" sort="Kwon, Taewoo" uniqKey="Kwon T" first="Taewoo" last="Kwon">Taewoo Kwon</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Park, Hye Lim" sort="Park, Hye Lim" uniqKey="Park H" first="Hye-Lim" last="Park">Hye-Lim Park</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Hun" sort="Kim, Hun" uniqKey="Kim H" first="Hun" last="Kim">Hun Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lee, Sang Myeong" sort="Lee, Sang Myeong" uniqKey="Lee S" first="Sang-Myeong" last="Lee">Sang-Myeong Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology, Chonbuk National University, Iksan 570-752, Republic of Korea. Electronic address: leesangm@jbnu.ac.kr.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Biotechnology, Chonbuk National University, Iksan 570-752</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nam, Jae Hwan" sort="Nam, Jae Hwan" uniqKey="Nam J" first="Jae-Hwan" last="Nam">Jae-Hwan Nam</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea. Electronic address: jhnam@catholic.ac.kr.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenoviruses, Human (genetics)</term>
<term>Adenoviruses, Human (immunology)</term>
<term>Adjuvants, Immunologic (administration & dosage)</term>
<term>Alum Compounds (administration & dosage)</term>
<term>Animals</term>
<term>Antibodies, Neutralizing (biosynthesis)</term>
<term>Antibodies, Viral (biosynthesis)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Coronavirus Infections (virology)</term>
<term>Female</term>
<term>Humans</term>
<term>Immunization Schedule</term>
<term>Immunization, Secondary (methods)</term>
<term>Immunogenicity, Vaccine</term>
<term>Immunoglobulin G (biosynthesis)</term>
<term>Lymphocyte Activation (drug effects)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term>
<term>Middle East Respiratory Syndrome Coronavirus (genetics)</term>
<term>Middle East Respiratory Syndrome Coronavirus (immunology)</term>
<term>Nanoparticles (administration & dosage)</term>
<term>Nanoparticles (chemistry)</term>
<term>Spike Glycoprotein, Coronavirus (administration & dosage)</term>
<term>Spike Glycoprotein, Coronavirus (genetics)</term>
<term>Spike Glycoprotein, Coronavirus (immunology)</term>
<term>Th1 Cells (drug effects)</term>
<term>Th1 Cells (immunology)</term>
<term>Th1 Cells (virology)</term>
<term>Th2 Cells (drug effects)</term>
<term>Th2 Cells (immunology)</term>
<term>Th2 Cells (virology)</term>
<term>Viral Vaccines (administration & dosage)</term>
<term>Viral Vaccines (genetics)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Activation des lymphocytes ()</term>
<term>Adjuvants immunologiques (administration et posologie)</term>
<term>Adénovirus humains (génétique)</term>
<term>Adénovirus humains (immunologie)</term>
<term>Alun (administration et posologie)</term>
<term>Animaux</term>
<term>Anticorps antiviraux (biosynthèse)</term>
<term>Anticorps neutralisants (biosynthèse)</term>
<term>Calendrier vaccinal</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (génétique)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie)</term>
<term>Femelle</term>
<term>Glycoprotéine de spicule des coronavirus (administration et posologie)</term>
<term>Glycoprotéine de spicule des coronavirus (génétique)</term>
<term>Glycoprotéine de spicule des coronavirus (immunologie)</term>
<term>Humains</term>
<term>Immunoglobuline G (biosynthèse)</term>
<term>Immunogénicité des vaccins</term>
<term>Infections à coronavirus ()</term>
<term>Infections à coronavirus (immunologie)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Lymphocytes auxiliaires Th1 ()</term>
<term>Lymphocytes auxiliaires Th1 (immunologie)</term>
<term>Lymphocytes auxiliaires Th1 (virologie)</term>
<term>Lymphocytes auxiliaires Th2 ()</term>
<term>Lymphocytes auxiliaires Th2 (immunologie)</term>
<term>Lymphocytes auxiliaires Th2 (virologie)</term>
<term>Nanoparticules ()</term>
<term>Nanoparticules (administration et posologie)</term>
<term>Rappel de vaccin ()</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Vaccins antiviraux (administration et posologie)</term>
<term>Vaccins antiviraux (génétique)</term>
<term>Vaccins antiviraux (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Alum Compounds</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
<term>Immunoglobulin G</term>
</keywords>
<keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Nanoparticles</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Alun</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Nanoparticules</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps neutralisants</term>
<term>Immunoglobuline G</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Nanoparticles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Lymphocyte Activation</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Th1 Cells</term>
<term>Th2 Cells</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Adenoviruses, Human</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Adénovirus humains</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Adénovirus humains</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Infections à coronavirus</term>
<term>Lymphocytes auxiliaires Th1</term>
<term>Lymphocytes auxiliaires Th2</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Adenoviruses, Human</term>
<term>Coronavirus Infections</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Th1 Cells</term>
<term>Th2 Cells</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Lymphocytes auxiliaires Th1</term>
<term>Lymphocytes auxiliaires Th2</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Th1 Cells</term>
<term>Th2 Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Female</term>
<term>Humans</term>
<term>Immunization Schedule</term>
<term>Immunogenicity, Vaccine</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Activation des lymphocytes</term>
<term>Animaux</term>
<term>Calendrier vaccinal</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Femelle</term>
<term>Humains</term>
<term>Immunogénicité des vaccins</term>
<term>Infections à coronavirus</term>
<term>Lymphocytes auxiliaires Th1</term>
<term>Lymphocytes auxiliaires Th2</term>
<term>Nanoparticules</term>
<term>Rappel de vaccin</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic and zoonotic virus with a fatality rate in humans of over 35%. Although several vaccine candidates have been developed, there is still no clinically available vaccine for MERS-CoV. In this study, we developed two types of MERS-CoV vaccines: a recombinant adenovirus serotype 5 encoding the MERS-CoV spike gene (Ad5/MERS) and spike protein nanoparticles formulated with aluminum (alum) adjuvant. Next, we tested a heterologous prime-boost vaccine strategy, which compared priming with Ad5/MERS and boosting with spike protein nanoparticles and vice versa, with homologous prime-boost vaccination comprising priming and boosting with either spike protein nanoparticles or Ad5/MERS. Although both types of vaccine could induce specific immunoglobulin G against MERS-CoV, neutralizing antibodies against MERS-CoV were induced only by heterologous prime-boost immunization and homologous immunization with spike protein nanoparticles. Interestingly, Th1 cell activation was induced by immunization schedules including Ad5/MERS, but not by those including only spike protein nanoparticles. Heterologous prime-boost vaccination regimens including Ad5/MERS elicited simultaneous Th1 and Th2 responses, but homologous prime-boost regimens did not. Thus, heterologous prime-boost may induce longer-lasting immune responses against MERS-CoV because of an appropriate balance of Th1/Th2 responses. However, both heterologous prime-boost and homologous spike protein nanoparticles vaccinations could provide protection from MERS-CoV challenge in mice. Our results demonstrate that heterologous immunization by priming with Ad5/MERS and boosting with spike protein nanoparticles could be an efficient prophylactic strategy against MERS-CoV infection.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29739720</PMID>
<DateCompleted><Year>2018</Year>
<Month>09</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>36</Volume>
<Issue>24</Issue>
<PubDate><Year>2018</Year>
<Month>06</Month>
<Day>07</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.</ArticleTitle>
<Pagination><MedlinePgn>3468-3476</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0264-410X(18)30598-X</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2018.04.082</ELocationID>
<Abstract><AbstractText>The Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic and zoonotic virus with a fatality rate in humans of over 35%. Although several vaccine candidates have been developed, there is still no clinically available vaccine for MERS-CoV. In this study, we developed two types of MERS-CoV vaccines: a recombinant adenovirus serotype 5 encoding the MERS-CoV spike gene (Ad5/MERS) and spike protein nanoparticles formulated with aluminum (alum) adjuvant. Next, we tested a heterologous prime-boost vaccine strategy, which compared priming with Ad5/MERS and boosting with spike protein nanoparticles and vice versa, with homologous prime-boost vaccination comprising priming and boosting with either spike protein nanoparticles or Ad5/MERS. Although both types of vaccine could induce specific immunoglobulin G against MERS-CoV, neutralizing antibodies against MERS-CoV were induced only by heterologous prime-boost immunization and homologous immunization with spike protein nanoparticles. Interestingly, Th1 cell activation was induced by immunization schedules including Ad5/MERS, but not by those including only spike protein nanoparticles. Heterologous prime-boost vaccination regimens including Ad5/MERS elicited simultaneous Th1 and Th2 responses, but homologous prime-boost regimens did not. Thus, heterologous prime-boost may induce longer-lasting immune responses against MERS-CoV because of an appropriate balance of Th1/Th2 responses. However, both heterologous prime-boost and homologous spike protein nanoparticles vaccinations could provide protection from MERS-CoV challenge in mice. Our results demonstrate that heterologous immunization by priming with Ad5/MERS and boosting with spike protein nanoparticles could be an efficient prophylactic strategy against MERS-CoV infection.</AbstractText>
<CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jung</LastName>
<ForeName>Seo-Yeon</ForeName>
<Initials>SY</Initials>
<AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kang</LastName>
<ForeName>Kyung Won</ForeName>
<Initials>KW</Initials>
<AffiliationInfo><Affiliation>Division of Biotechnology, Chonbuk National University, Iksan 570-752, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Eun-Young</ForeName>
<Initials>EY</Initials>
<AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Seo</LastName>
<ForeName>Dong-Won</ForeName>
<Initials>DW</Initials>
<AffiliationInfo><Affiliation>Division of Biotechnology, Chonbuk National University, Iksan 570-752, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Hong-Lim</ForeName>
<Initials>HL</Initials>
<AffiliationInfo><Affiliation>Seoul St. Mary's Hospital, School of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Hak</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kwon</LastName>
<ForeName>TaeWoo</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Park</LastName>
<ForeName>Hye-Lim</ForeName>
<Initials>HL</Initials>
<AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Hun</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Sang-Myeong</ForeName>
<Initials>SM</Initials>
<AffiliationInfo><Affiliation>Division of Biotechnology, Chonbuk National University, Iksan 570-752, Republic of Korea. Electronic address: leesangm@jbnu.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nam</LastName>
<ForeName>Jae-Hwan</ForeName>
<Initials>JH</Initials>
<AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea. Electronic address: jhnam@catholic.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>05</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000534">Alum Compounds</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000260" MajorTopicYN="N">Adenoviruses, Human</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000534" MajorTopicYN="N">Alum Compounds</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018418" MajorTopicYN="N">Th2 Cells</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Adenovirus 5</Keyword>
<Keyword MajorTopicYN="Y">Heterologous prime–boost</Keyword>
<Keyword MajorTopicYN="Y">MERS-CoV</Keyword>
<Keyword MajorTopicYN="Y">Th1</Keyword>
<Keyword MajorTopicYN="Y">Th2</Keyword>
<Keyword MajorTopicYN="Y">Vaccine</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year>
<Month>11</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2018</Year>
<Month>04</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>04</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>5</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2018</Year>
<Month>9</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>5</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">29739720</ArticleId>
<ArticleId IdType="pii">S0264-410X(18)30598-X</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2018.04.082</ArticleId>
<ArticleId IdType="pmc">PMC7115429</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Hum Gene Ther. 1999 Nov 20;10(17):2823-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10584928</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Commun. 2015 Jul 28;6:7712</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26218507</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Front Biosci. 2007 Jan 01;12:1833-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17127424</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2015 Aug;89(16):8651-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26018172</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2006 May 11;441(7090):239-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16625206</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2015 Apr 16;202:151-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25445336</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Res. 2013 Aug;23(8):986-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23835475</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Gene Ther. 1998 Jul;5(7):995-1002</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9813671</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Am J Epidemiol. 1969 Apr;89(4):422-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4305198</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2003 Oct;77(20):10780-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14512528</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Blood. 2007 Sep 15;110(6):1916-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17510320</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Am J Pathol. 2016 Jan;186(1):78-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26597880</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2014 Oct 14;32(45):5975-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25192975</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 1998 Oct 16;282(5388):476-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9774275</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 May;79(10):6516-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15858035</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2016 Jul;494:215-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27123586</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Microbiol Rev. 2015 Apr;28(2):465-522</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25810418</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Am J Respir Crit Care Med. 2003 Nov 1;168(9):1075-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12816738</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2014 Apr 11;32(18):2100-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24560617</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Gene Ther. 1998 Jun;5(6):740-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9747453</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2013 Dec 04;8(12):e81587</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24324708</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2004 May 15;172(10):6290-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15128818</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunol Res. 1999;20(2):147-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10580639</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2013 Nov;87(21):11950-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23986586</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Gene Ther. 2011 Aug;11(4):307-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21453277</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2016 Sep;133:165-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27468951</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2017 Jun 27;35(30):3780-3788</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28579232</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2003 Aug;77(15):8263-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12857895</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Drug Discov. 2016 May;15(5):327-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26868298</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Immunol. 2017 Aug 4;2(14):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28778905</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Annu Rev Med. 2004;55:355-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14746526</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunology. 2015 Aug;145(4):476-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25762305</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2009 May 15;182(10):6587-99</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19414814</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2015;11(5):1244-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25874632</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2014 May 30;32(26):3169-3174</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24736006</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2008;3(10):e3548</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18958172</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2017 Mar 14;35(12):1586-1589</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28237499</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Transl Med. 2015 Aug 19;7(301):301ra132</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26290414</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2010 Aug 1;185(3):1513-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20610651</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Pathog. 2015 Mar 13;11(3):e1004757</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25769044</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000910 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000910 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:29739720
   |texte=   Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:29739720" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.

Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki